Michael Basler

Dr. Michael Basler

Division of Immunology, Department of Biology, University of Konstanz, D-78457 Konstanz, Germany
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2009 in Nature Medicine
Verified
Journal Article
Closed access
TMTony Muchamuel
Tony Muchamuel
Michael BaslerMichael Basler
Michael Basler
MAMonette A Aujay
Monette A Aujay
ESErika Suzuki
Erika Suzuki
KKKhalid W Kalim
Khalid W Kalim
MGMarcus Groettrup
Marcus Groettrup

1 February 2012 in Cell
Verified
Journal Article
Closed access
EHEva M. Huber
Eva M. Huber
Michael BaslerMichael Basler
Michael Basler
RSRicarda Schwab
Ricarda Schwab
WHWolfgang Heinemeyer
Wolfgang Heinemeyer
CKChristopher J. Kirk
Christopher J. Kirk
MGMichael Groll
Michael Groll

11 December 2009 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
Marcus GroettrupMarcus Groettrup
Marcus Groettrup
CKChristopher J. Kirk
Christopher J. Kirk
Michael BaslerMichael Basler
Michael Basler

1 February 2013 in Current Opinion in Immunology
Verified
Journal Article
Closed access
Michael BaslerMichael Basler
Michael Basler
CKChristopher J Kirk
Christopher J Kirk
MGMarcus Groettrup
Marcus Groettrup

1 July 2010 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
Michael BaslerMichael Basler
Michael Basler
MDMaya Dajee
Maya Dajee
CMCarlo Moll
Carlo Moll
MGMarcus Groettrup
Marcus Groettrup
CKChristopher J. Kirk
Christopher J. Kirk
The proteasome, a multicatalytic protease, is responsible for the degradation of intracellular proteins. Stimulation of cells with inflammatory cytokines, such as IFN-γ, leads to the replacement of the constitutive catalytic proteasome subunits by the inducible subunits low molecular mass polypeptide (LMP)2 (β1i), multicatalytic endopeptidase complex-like-1 (β2i), and LMP7 (β5i), which are required for the production of certain MHC class I-restricted T cell epitopes. In this study, we investigated the effect of immunoproteasomes on the development of dextran sulfate sodium-induced colitis. Colitis induction in LMP2-, LMP7-, and multicatalytic endopeptidase complex-like-1–deficient mice caused reduced weight loss compared with wild-type mice. Although colon lengths were shortened in wild-type mice, no reduction was observed in immunoproteasome-deficient mice. In accordance with this, proinflammatory cytokines, such as TNF-α and IL-1β, were not upregulated in these mice. Blockage of LMP7 by a novel LMP7-selective inhibitor (PR-957) strongly reduced pathological symptoms of dextran sulfate sodium-induced colitis. Production of numerous cytokines in PR-957–treated mice was suppressed, resulting in reduced inflammation and tissue destruction. Taken together, these results demonstrate that an immunoproteasome-specific inhibitor can be used to attenuate autoimmune diseases like colitis.

7 January 2014 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
Michael BaslerMichael Basler
Michael Basler
SMSarah Mundt
Sarah Mundt
TMTony Muchamuel
Tony Muchamuel
CMCarlo Moll
Carlo Moll
JJJing Jiang
Jing Jiang
CKChristopher J. Kirk
Christopher J. Kirk
Multiple sclerosis (MS) is a chronic demyelinating immune mediated disease of the central nervous system. The immunoproteasome is a distinct class of proteasomes found predominantly in monocytes and lymphocytes. Recently, we demonstrated a novel function of immunoproteasomes in cytokine production and T cell differentiation. In this study, we investigated the therapeutic efficacy of an inhibitor of the immunoproteasome (ONX 0914) in two different mouse models of MS. ONX 0914 attenuated disease progression after active and passive induction of experimental autoimmune encephalomyelitis (EAE), both in MOG 35–55 and PLP 139–151 ‐induced EAE. Isolation of lymphocytes from the brain or spinal cord revealed a strong reduction of cytokine‐producing CD4 + cells in ONX 0914 treated mice. Additionally, ONX 0914 treatment prevented disease exacerbation in a relapsing‐remitting model. An analysis of draining lymph nodes after induction of EAE revealed that the differentiation to Th17 or Th1 cells was strongly impaired in ONX 0914 treated mice. These results implicate the immunoproteasome in the development of EAE and suggest that immunoproteasome inhibitors are promising drugs for the treatment of MS.